The purpose of this study is to determine whether using hyperbaric oxygen (HBO) improves wound healing for patients who have a crush injury. The comparison of the prospective intervention group to the retrospective matched cohort aims to show that HBO can improve wound healing and decrease poor outcomes for patients with crush injuries. The information gained from this small study will serve as a basis for a follow-up prospective, randomized control trial to further delineate the role of HBO in a larger patient population.

开始日期2021-09-01

申办/合作机构

NYU Langone Health

[+1]

NCT04066088 / Withdrawn临床4期IIT

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects.

开始日期2019-12-01

申办/合作机构

NYU Langone Health

[+1]

NCT04050852 / Withdrawn早期临床1期IIT

Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments

It is well known that patients with spinal muscular atrophy (SMA) have progressive decline of respiratory muscle function. Therapy traditionally involved supportive means to ensure optimal nutrition and airway clearance. Nusinersen (spinraza) is a disease-modifying medication approved for treatment of SMA in pediatric and adult patients. The goal of this study is to observe pulmonary function test (PFT) changes and respiratory muscle strength trends throughout the first year of treatment. A prospective, longitudinal study measuring pulmonary function testing (PFTs) changes in spinal muscular atrophy (SMA) patients. Patients will be patients with SMA who are approved and maintained on nusinersen. Patient will have a baseline PFT. Investigators will repeat PFT at 3, 6, and 12 months while on nusinersen treatment.

开始日期2019-07-17

申办/合作机构

NYU Langone Health

[+1]

100 项与 Winthrop-University Hospital, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Winthrop-University Hospital, Inc. 相关的专利（医药）

登录后查看更多信息

3,764

项与 Winthrop-University Hospital, Inc. 相关的文献（医药）

2024-06-01·Cardiovascular Drugs and Therapy

Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study

Article

作者: O'Cochlain, D Fearghas ; So, Derek ; Dzavik, Vlad ; Pereira, Naveen ; Mathew, Roy O ; Rihal, Charanjit S ; El-Hajjar, Mohammed ; Goodman, Shaun ; Murthy, Vishakantha ; Abdul-Nour, Khaled ; Levisay, Justin ; Lennon, Ryan ; Rosenberg, Yves D ; Lyubarova, Radmila ; Sidhu, Mandeep S ; Graham, John ; Weitz, Steven ; Farkouh, Michael E ; Marzo, Kevin ; Yager, Neil

PURPOSEChronic kidney disease (CKD) is a risk factor for ischemic and bleeding events with dual antiplatelet therapy after percutaneous coronary intervention (PCI). Whether the presence of CYP2C19 loss of function (LOF) alleles modifies this risk, and whether a genotype-guided (GG) escalation of P2Y₁₂ inhibitor therapy post PCI is safe in this population is unclear.METHODSThis was a post hoc analysis of randomized patients in TAILOR PCI. Patients were divided into two groups based on estimated glomerular filtration rate (eGFR) threshold of < 60 ml/min/1.73 m² for CKD (n = 539) and non-CKD (n = 4276). The aggregate of cardiovascular death, stroke, myocardial infarction, stent thrombosis, and severe recurrent coronary ischemia at 12-months post-PCI was assessed as the primary endpoint. Secondary endpoint was major or minor bleeding.RESULTSMean (standard deviation) eGFR among patients with CKD was 49.5 (8.4) ml/min/1.72 m². Among all patients, there was no significant interaction between randomized strategy and CKD status for any endpoint. Among LOF carriers, the interaction between randomized strategy and CKD status on composite ischemic outcome was not significant (p = 0.2). GG strategy was not associated with an increased risk of bleeding in either CKD group.CONCLUSIONSIn this exploratory analysis, escalation of P2Y₁₂ inhibitor therapy following a GG strategy did not reduce the primary outcome in CKD. However, P2Y₁₂ inhibitor escalation following a GG strategy was not associated with increased bleeding risk in CKD. Larger studies in CKD are needed.CLINICAL TRIAL REGISTRATIONhttps://clinicaltrials.gov/ct2/show/NCT01742117?term=TAILOR-PCI&draw=2&rank=1 . NCT01742117.

2023-09-01·American Journal of Obstetrics & Gynecology MFM

Breastfeeding initiation and duration among people with mild chronic hypertension: a secondary analysis of the Chronic Hypertension and Pregnancy trial

Article

作者: Hoffman, Matthew ; Reddy, Uma M ; Su, Emily ; Tita, Alan T ; Metz, Torri D ; Haas, David M ; Hughes, Brenna L ; Foroutan, Janelle ; Baker, Susan ; Krishna, Iris ; Longo, Sherri ; El-Sayed, Yasser Y ; Saade, George R ; Oparil, Suzanne ; Bell, Joseph ; Gibson, Kelly ; Skupski, Daniel ; Simhan, Hyagriv N ; Frey, Heather ; Plante, Lauren ; Rosen, Todd ; Norton, Mary E ; Szychowski, Jeff M ; Casey, Brian ; Edwards, Rodney K ; Nguyen, Nicki ; Kinzler, Wendy ; Tuuli, Methodius ; Hoppe, Kara K ; Ambalavanan, Namasivayam ; Esplin, Sean ; Sibai, Baha ; Palatnik, Anna ; Boggess, Kim ; Ogunyemi, Dotun ; Antoniewicz, Leah ; Owens, Michelle Y ; Goulding, Alison N ; Leach, Justin M ; Harper, Lorie M ; Dugoff, Lorraine ; Lawrence, Kirsten

BACKGROUNDIncreased duration of breastfeeding improves maternal cardiovascular health and may be especially beneficial in high-risk populations, such as those with chronic hypertension. Others have shown that individuals with hypertension are less likely to breastfeed, and there has been limited research aimed at supporting breastfeeding goals in this population. The impact of perinatal blood pressure control on breastfeeding outcomes among people with chronic hypertension is unknown.OBJECTIVEThis study aimed to evaluate whether breastfeeding initiation and short-term duration assessed at the postpartum clinic visit differed according to perinatal blood pressure treatment strategy (targeting blood pressure <140/90 mm Hg vs reserving antihypertensive treatment for blood pressure ≥160/105 mm Hg).STUDY DESIGNWe performed a secondary analysis of the Chronic Hypertension and Pregnancy trial. This was an open-label, multicenter, randomized trial where pregnant participants with mild chronic hypertension were randomized to receive antihypertensive medications with goal blood pressure <140/90 mm Hg (active treatment) or deferred treatment until blood pressure ≥160/105 mm Hg (control). The primary outcome was initiation and duration of breastfeeding, assessed at the postpartum clinic visit. We performed bivariate analyses and log-binomial and cumulative logit regression models, adjusting models for variables that were unbalanced in bivariate analyses. We performed additional analyses to explore the relationship between breastfeeding duration and blood pressure measurements at the postpartum visit.RESULTSOf the 2408 participants from the Chronic Hypertension and Pregnancy trial, 1444 (60%) attended the postpartum study visit and provided breastfeeding information. Participants in the active treatment group had different body mass index class distribution and earlier gestational age at enrollment, and (by design) were more often discharged on antihypertensives. Breastfeeding outcomes did not differ significantly by treatment group. In the active and control treatment groups, 563 (77.5%) and 561 (78.1%) initiated breastfeeding, and mean durations of breastfeeding were 6.5±2.3 and 6.3±2.1 weeks, respectively. The probability of ever breastfeeding (adjusted relative risk, 0.99; 95% confidence interval, 0.93-1.05), current breastfeeding at postpartum visit (adjusted relative risk, 1.01; 95% confidence interval, 0.94-1.10), and weeks of breastfeeding (adjusted odds ratio, 0.87; 95% confidence interval, 0.68-1.12) did not differ by treatment group. Increased duration (≥2 vs <2 weeks) of breastfeeding was associated with slightly lower blood pressure measurements at the postpartum visit, but these differences were not significant in adjusted models.CONCLUSIONIn a secondary analysis of the cohort of Chronic Hypertension and Pregnancy trial participants who attended the postpartum study visit and provided breastfeeding information (60% of original trial participants), breastfeeding outcomes did not differ significantly by treatment group. This suggests that maintaining goal blood pressure <140/90 mm Hg throughout the perinatal period is associated with neither harm nor benefit for short-term breastfeeding goals. Further study is needed to understand long-term breastfeeding outcomes among individuals with chronic hypertension and how to support this population in achieving their breastfeeding goals.

2022-10-01·Journal of Clinical Oncology

Racial disparities among patients with multiple myeloma enrolled in clinical trials.

作者: Bari, Thoasin ; Islam, Shahidul ; Nishat, Nabilah ; Braunstein, Marc Justin

89 Background: Tremendous therapeutic progress has been made over the past decade in the field of multiple myeloma (MM). Although the incidence of MM is twice as high for black compared to white individuals, mortality rates remain higher for black patients (Marinac, et al. Blood Ca J 2020). In addition, black Americans are significantly less likely to participate in clinical trials in general (Hong, et al. Am J Prev Med 2021), leading to disproportionate enrollment in studies of novel agents. Various factors may account for these disparities, including access to clinical trials, clinician bias, and hesitancy to enroll in clinical trials among different patient populations. Furthermore, underrepresentation of racial groups within clinical trials impacts the generalizability of important findings from these studies. Here we characterized the racial representation of MM clinical trials. Methods: Randomized clinical trials focused on MM interventions published between 2012-2022 were included. We screened 431 publications during this period and characterized racial demographics as available in the literature. A two-sided Cochran-Armitage Trend Test was used to assess if there was a linear trend in the percentage of black participants in clinical trials over time. Results: Among 431 studies published over the past 10 years, 76 collected over past 5 years that included racial demographic details were included. Among the 38,830 participants, 87.5% were white, 4.8% were black, and 7.7% were other (reported as either “Asian”, “mixed”, or “other”). There was a significant trend toward increased enrollment comparing over time between 2018 to 2021 (2.1 to 7.0%, p < 0.001 for trend), however black individual remained largely underrepresented in all these studies. Conclusions: While the number of black participating in randomized controlled trials involving MM patients over the past five years is significantly increasing, these studies included a disproportionate number of white participants, despite the incidence of MM being higher for black patients. Efforts are underway in the field to enhance enrollment of underrepresented populations, including a recent randomized study that included 19% black MM patients (Richardson, et al. New Eng J Med 2022). Our study was limited due to many trials not reporting details about racial demographics until relatively recently. Further investigations required to examine the reasons underlying racial disparities in MM trial recruitment and enrollment.

项与 Winthrop-University Hospital, Inc. 相关的新闻（医药）

2024-10-29

·PRNewswire

The Inner Circle acknowledges, Peter M. Farrugia as a 2024 Pinnacle Lifetime Member

COLTS NECK, N.J., Oct. 28, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Peter M. Farrugia is acknowledged as a 2024 Pinnacle Lifetime Member for his contributions to the field of Interventional Cardiology. Dr. Farrugia pursued higher education at Kings College where he earned a Bachelor of Science degree in Biology and Molecular Biology with Summa Cum Laude honors. He then obtained his MD at the Renaissance School of Medicine at Stony Brook University. He completed his Internal Medicine Program at SUNY Stony Brook, followed by a cardiovascular disease fellowship at St. Vincent's Catholic Medical Center in Manhattan. He further specialized in interventional cardiology through training at Winthrop University Hospital. The doctor holds certifications in cardiovascular disease and interventional cardiology, as well as being a Registered Physician in Vascular Interpretation (RPVI). A dedicated interventional cardiologist and vascular specialist, Dr. Farrugia notes that he has been instrumental in providing high-quality cardiac and vascular care to patients in Monmouth and Ocean County. He currently serves as the CEO of Advanced Heart and Vascular of Central Jersey which he explained is a practice that prioritizes the physician-patient relationship and focuses on delivering exceptional care. The doctor explained that interventional cardiology involves catheter-based treatments for structural heart diseases, while vascular surgery addresses vascular issues through medical therapy, minimally-invasive procedures, and surgical reconstruction. With more than 10 years in the field, Dr. Farrugia is an expert in interventional cardiology and vascular care, and is well-known in the field for advanced techniques and procedures aimed at diagnosing and treating structural heart diseases and vascular conditions. A leader in the field, the doctor is affiliated with many professional organizations, including the American College of Cardiology (FACC). During his tenure as an interventional cardiologist, Dr. Farrugia has held key roles in various medical institutions, including serving as the Director of Outpatient Vascular Medicine and Chief of the Cardiac Catheterization Lab at Monmouth Medical Center. Dr. Farrugia is credited with improving care delivery models, and has received recognition as a Fellow of the American College of Cardiology (FACC). Aside from his professional pursuits, Dr. Farrugia is a sports coach, and trains in ballroom dancing with his family of which he also enjoys spending his spare time. Contributing positively to his community, the doctor acknowledges the unwavering support of his wife, Erin, and their four children. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2024-07-02

·PRNewswire

The Inner Circle acknowledges, Peter M. Farrugia as a 2024 Pinnacle Lifetime Member

COLTS NECK, N.J., July 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Peter M. Farrugia is acknowledged as a 2024 Pinnacle Lifetime Member for his contributions to the field of Interventional Cardiology. Dr. Farrugia pursued higher education at Kings College where he earned a Bachelor of Science degree in Biology and Molecular Biology with Summa Cum Laude honors. He then obtained his MD at the Renaissance School of Medicine at Stony Brook University. He completed his Internal Medicine Program at SUNY Stony Brook, followed by a cardiovascular disease fellowship at St. Vincent's Catholic Medical Center in Manhattan. He further specialized in interventional cardiology through training at Winthrop University Hospital. The doctor holds certifications in cardiovascular disease and interventional cardiology, as well as being a Registered Physician in Vascular Interpretation (RPVI). A dedicated interventional cardiologist and vascular specialist, Dr. Farrugia notes that he has been instrumental in providing high-quality cardiac and vascular care to patients in Monmouth and Ocean County. He currently serves as the CEO of Advanced Heart and Vascular of Central Jersey which he explained is a practice that prioritizes the physician-patient relationship and focuses on delivering exceptional care. The doctor explained that interventional cardiology involves catheter-based treatments for structural heart diseases, while vascular surgery addresses vascular issues through medical therapy, minimally-invasive procedures, and surgical reconstruction. With more than 10 years in the field, Dr. Farrugia is an expert in interventional cardiology and vascular care, and is well-known in the field for advanced techniques and procedures aimed at diagnosing and treating structural heart diseases and vascular conditions. A leader in the field, the doctor is affiliated with many professional organizations, including the American College of Cardiology (FACC). During his tenure as an interventional cardiologist, Dr. Farrugia has held key roles in various medical institutions, including serving as the Director of Outpatient Vascular Medicine and Chief of the Cardiac Catheterization Lab at Monmouth Medical Center. Dr. Farrugia is credited with improving care delivery models, and has received recognition as a Fellow of the American College of Cardiology (FACC). Aside from his professional pursuits, Dr. Farrugia is a sports coach, and trains in ballroom dancing with his family of which he also enjoys spending his spare time. Contributing positively to his community, the doctor acknowledges the unwavering support of his wife, Erin, and their four children. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

高管变更

2023-08-21

·PRNewswire

The Inner Circle Acknowledges, Josel Doyle as a Pinnacle Platinum Healthcare Professional for her contributions to the field of Neonatology

TOPEKA, Kan., Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to the field of Neonatology. Dr. Doyle pursued higher education at St. Georges University School of Medicine where she earned an undergraduate and medical degrees. She completed a residency in pediatrics and a fellowship in neonatal-perinatal medicine at Winthrop University Hospital. Recognized for her leadership early in her career, she also served as Chief Resident at Stony Brook University Hospital. Continue Reading Josel Avion Akyla Doyle Dr. Doyle currently works at Pediatrix Neonatology of Topeka where she and her team, all board-certified neonatologists and certified neonatal nurse practitioners (NNPs), care for premature and critically ill newborns. She explained that they began providing services in the St. Francis Health Level II NICU in Topeka in 2013 and also offer newborn hearing services in several area hospitals. Dr. Doyle explained that neonatology is a subspecialty of pediatrics that consists of the medical care of newborn infants, especially ill or premature newborns. It is a hospital-based specialty and is usually practiced in neonatal intensive care units. She said that neonatologists generally diagnose and treat newborns with conditions such as breathing disorders, infections, and birth defects as well as coordinating care and medically managing newborns born prematurely, critically ill, or in need of surgery. Dr. Doyle is dedicated and passionate about providing the latest advancements in her field and her clinical interests include neonatal nutrition; developmental outcomes; and respiratory distress syndrome, which are all essential components of the care of premature and critically ill infants. She is a member of numerous professional organizations, including the American Academy of Pediatrics; the Kansas Perinatal Collaborative on Neonatal Abstinence Syndrome (NAS); and Stormont Vail Hospitals NAS task force where she helps to develop policies and practices aimed at improving the care of infants affected by substance use disorders. The doctor is highly sought after for her skills and leadership abilities. As such, she is also on Stormont's Family-Centered Care Committee and serves on the NICU Developmental and Relationship Committee. has also When considering her achievements during her career, Dr. Doyle credits her parents and her faith in God for instilling in her a strong sense of purpose and the values of hard work, compassion, and dedication. She notes that her love for the profession been a driving force in her success. She is deeply committed to providing the best possible care to her patients and is constantly seeking new ways to improve outcomes and enhance the patient's experience. Contact: Katherine Green, 516-825-5634, editorial@continentalwhoswho.com SOURCE The Inner Circle